Matthey 2013.

Study characteristics
Methods	Design: parallel Duration: 7 weeks Assessment: baseline and post‐intervention Country: Switzerland
Participants	Pain condition: fibromyalgia Population: adult women with fibromyalgia Minimum pain intensity: ≥ 40 on 0‐100 VAS Inclusion criteria Women who met the ACR fibromyalgia criteria Pain intensity of ≥ 40 on 0‐100 VAS at baseline Exclusion criteria Physical and mental health comorbidities Total participants randomised: 80 Age in years (mean): 49.7 Gender: 80/80 were female Pain duration in years (mean, SD): NR
Interventions	Placebo n = 39 Inert Milnacipran 100‐200 mg n = 40 SNRI Flexible dosing to 100 mg, 150 mg, or 200 mg per day based on tolerability
Outcomes	Pain intensity Quality of life Physical function Mood Sleep Withdrawal
Missing data methods	ITT wit h LOCF
Funding source	Pharmaceutical: This trial was supported by a grant from Pierre Fabre Médicament.
Conflicts of interest	"Each author certifies that he or she, or a member of his or her immediate family, has no commercial association, (i.e., consultancies, stock ownership, equity interest, patent/licensing arrangements, etc.) that might post a COI in connection with the submitted manuscript."
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	A randomisation list was computer‐generated.
Allocation concealment (selection bias)	Low risk	Allocation of treatments was done by the investigator according to the chronological order of the occurring visit 2
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	State double‐blind but not enough information about study drug appearance and dosing
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Self‐reported outcomes from participants, but unsure of blinding procedures
Incomplete outcome data (attrition bias) All outcomes	High risk	ITT with LOCF, high attrition Attrition Total: 37/80 (46.3%) Placebo: 16/40 (40.0%) Milnacipran 100‐200 mg: 21/40 (52.5%)
Selective reporting (reporting bias)	Unclear risk	No changes to protocol, but it's registered 2 years after trial start
Other bias	Low risk	No other sources of bias were identified.